NCT04474470
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Breast cancer patients are only eligible for Portion 1 of the study
Exclusions: Patients with active, untreated central nervous system (CNS) metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04474470